BidaskClub upgraded shares of BeiGene (NASDAQ:BGNE) from a buy rating to a strong-buy rating in a research report report published on Wednesday, March 21st.
A number of other analysts also recently issued reports on BGNE. Maxim Group set a $120.00 price objective on shares of BeiGene and gave the company a buy rating in a report on Monday, December 11th. Cowen reiterated a buy rating on shares of BeiGene in a report on Monday, December 11th. ValuEngine downgraded shares of BeiGene from a hold rating to a sell rating in a report on Wednesday, January 3rd. Finally, Zacks Investment Research downgraded shares of BeiGene from a hold rating to a sell rating in a report on Monday, January 8th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $151.83.
Shares of NASDAQ BGNE traded down $0.29 during midday trading on Wednesday, reaching $171.53. The company’s stock had a trading volume of 322,480 shares, compared to its average volume of 400,408. The company has a quick ratio of 6.02, a current ratio of 6.09 and a debt-to-equity ratio of 0.23. BeiGene has a fifty-two week low of $34.36 and a fifty-two week high of $182.79. The company has a market capitalization of $9,322.45, a PE ratio of -76.92 and a beta of 0.23.
BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.40). The firm had revenue of $18.17 million for the quarter, compared to the consensus estimate of $23.00 million. sell-side analysts expect that BeiGene will post -7.69 EPS for the current year.
In related news, EVP Ji Li sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $146.88, for a total transaction of $1,468,800.00. Following the transaction, the executive vice president now directly owns 10,000 shares in the company, valued at $1,468,800. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Bros. Advisors Lp Baker acquired 1,980,198 shares of BeiGene stock in a transaction on Thursday, January 18th. The shares were bought at an average cost of $101.00 per share, with a total value of $199,999,998.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 194,210 shares of company stock worth $29,041,676. 19.90% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP bought a new position in BeiGene during the third quarter worth $160,000. Tower Research Capital LLC TRC bought a new position in BeiGene during the fourth quarter worth $182,000. Comerica Bank bought a new position in BeiGene during the fourth quarter worth $246,000. Teachers Retirement System of The State of Kentucky bought a new position in BeiGene during the third quarter worth $248,000. Finally, Mackenzie Financial Corp bought a new position in BeiGene during the fourth quarter worth $250,000. 51.47% of the stock is owned by hedge funds and other institutional investors.
WARNING: “BidaskClub Upgrades BeiGene (BGNE) to “Strong-Buy”” was published by Macon Daily and is the property of of Macon Daily. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://macondaily.com/2018/04/12/beigene-bgne-stock-rating-upgraded-by-bidaskclub-updated-updated-updated.html.
BeiGene Company Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.